P-480: Continuous glucose monitoring program in a reference center in southern Brazil
A Vigo, G Simoni, E Cechinel, J Lee, D Schuh, J Lemos, P SilvaAbstract
Introduction
Type 1 diabetes (T1D) requires complex management. Utilizing new technologies like continuous glucose monitoring (CGM) is essential to improve glycemic control, reduce complications, improve patients’ quality of life, and lower public health costs.
Objectives
To demonstrate the impact of CGM on pediatric T1D patients.
Methods
CGM on 120 pediatric T1D patients at the Joana de Gusmão Children’s Hospital (HIJG) in Santa Catarina (SC), supported by SES-SC, from January 2024 to April 2025.
Results
There were 83 hospitalizations for the treatment of T1D, 61% being new-onset cases. Of the remaining patients, only 4 of them were using CGM, and none of those were due to diabetic ketoacidosis (DKA), but for treatment adjustment due to inadequate glycemic control, according to data analysis from the CGM, with the aim of preventing clinical decompensation. Analyzing the data from these patients, the estimated value of glycated hemoglobin (HbA1c) by the CGM was on average 7.5%. As for hypoglycemia, there was less than 1 event recorded per day. The healthcare team observed greater adherence to treatment and an improvement in the quality of life for patients and their families.
Conclusions
CGM resulted in a low number of acute complications related to T1D. Its data allowed for greater monitoring of these patients, with the possibility of adjustments in treatment, preventing clinical decompensation. In addition, we observed an improvement in quality of life and adherence to treatment. It is also possible to infer that the use of this device has a positive impact on public health costs.